Aligos Therapeutics (ALGS) Non-Current Assets (2021 - 2025)
Historic Non-Current Assets for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $6.3 million.
- Aligos Therapeutics' Non-Current Assets fell 2644.12% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year decrease of 2514.82%. This contributed to the annual value of $8.0 million for FY2024, which is 2384.37% down from last year.
- Latest data reveals that Aligos Therapeutics reported Non-Current Assets of $6.3 million as of Q3 2025, which was down 2644.12% from $6.8 million recorded in Q2 2025.
- Aligos Therapeutics' Non-Current Assets' 5-year high stood at $30.9 million during Q4 2021, with a 5-year trough of $6.3 million in Q3 2025.
- Moreover, its 5-year median value for Non-Current Assets was $11.9 million (2023), whereas its average is $12.4 million.
- Over the last 5 years, Aligos Therapeutics' Non-Current Assets had its largest YoY gain of 462.14% in 2022, and its largest YoY loss of 5751.17% in 2022.
- Quarter analysis of 5 years shows Aligos Therapeutics' Non-Current Assets stood at $30.9 million in 2021, then plummeted by 57.51% to $13.1 million in 2022, then dropped by 20.57% to $10.4 million in 2023, then fell by 23.84% to $8.0 million in 2024, then fell by 20.42% to $6.3 million in 2025.
- Its Non-Current Assets was $6.3 million in Q3 2025, compared to $6.8 million in Q2 2025 and $7.5 million in Q1 2025.